508 Results for "

AML

" in MedChemExpress (MCE) Product Catalog:
Products (508)

508 Results for "AML" in MCE Product Catalog:

113
113 Publications Verification
Art. -Nr.: HY-134836
CAS. Nr.: 2499663-01-1
Reinheit:  99.86%
Target:  

Apoptosis METTL3

Forschungsgebiete:  

Cancer

STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC50 of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML) .
loading...
    loading...
71
71 Cited Publications
Art. -Nr.: HY-50907
CAS. Nr.: 852808-04-9
ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .
loading...
    loading...
48
48 Cited Publications
Art. -Nr.: HY-14217
CAS. Nr.: 1132827-21-4
Reinheit:  99.81%
Synonyms: AC220 dihydrochloride
Target:  

FLT3 Apoptosis PDGFR c-Kit

Forschungsgebiete:  

Cancer

Quizartinib (AC220) dihydrochloride is an orally active, potent and selective FLT3 inhibitor. Quizartinib dihydrochloride inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib dihydrochloride inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib dihydrochloride can be used for the research of cancer .
loading...
    loading...
29
29 Cited Publications
Art. -Nr.: HY-127103
CAS. Nr.: 2243736-45-8
Reinheit:  98.64%
Target:  

Apoptosis

Forschungsgebiete:  

Cancer

FB23-2 is a potent and selective inhibitor of mRNA N 6-methyladenosine (m 6A) demethylase FTO, with an IC50 of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML) .
loading...
    loading...
28
28 Cited Publications
Art. -Nr.: HY-112037
CAS. Nr.: 1570496-34-2
Reinheit:  99.68%
Synonyms: IACS-10759
IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research .
loading...
    loading...
28
28 Cited Publications
Art. -Nr.: HY-112037A
CAS. Nr.: 1807523-99-4
Reinheit:  99.58%
Synonyms: IACS-10759 hydrochloride
IACS-010759 hydrochlorideis an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 hydrochlorideinhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 hydrochloride has the potential for relapsed/refractory AML and solid tumors research .
loading...
    loading...
20
20 Cited Publications
Art. -Nr.: HY-18767
CAS. Nr.: 1448347-49-6
Synonyms: AG-120
Forschungsgebiete:  

Metabolic Disease Cancer

Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity .
loading...
    loading...
19
19 Cited Publications
Art. -Nr.: HY-16379B
CAS. Nr.: 1228923-42-9
Synonyms: SB1518 citrate
Target:  

JAK FLT3

Forschungsgebiete:  

Cancer

Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2 V617F mutant (IC50=19 nM). Pacritinib citrate also inhibits FLT3 (IC50=22 nM) and its mutant FLT3 D835Y (IC50=6 nM). Pacritinib citrate can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) .
loading...
    loading...
17
17 Cited Publications
Art. -Nr.: HY-136175
CAS. Nr.: 2169919-21-3
Reinheit:  99.76%
Synonyms: SNDX-5613
Forschungsgebiete:  

Cancer

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .
loading...
    loading...
16
16 Cited Publications
Art. -Nr.: HY-15255
CAS. Nr.: 167354-41-8
Reinheit:  99.90%
Synonyms: RS 33295-198; LY-335979
Target:  

P-glycoprotein

Forschungsgebiete:  

Cancer

Zosuquidar (LY335979) is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .
loading...
    loading...
16
16 Cited Publications
Art. -Nr.: HY-50671
CAS. Nr.: 167465-36-3
Synonyms: RS 33295-198 trihydrochloride; LY-335979 trihydrochloride
Target:  

P-glycoprotein

Forschungsgebiete:  

Cancer

Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .
loading...
    loading...
12
12 Cited Publications
Art. -Nr.: HY-15229
CAS. Nr.: 929904-85-8
Reinheit:  98.04%
Synonyms: SGI-110 sodium; S-110 sodium
Target:  

DNA Methyltransferase

Forschungsgebiete:  

Cancer

Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .
loading...
    loading...
11
11 Cited Publications
Art. -Nr.: HY-101025
CAS. Nr.: 1610022-76-8
Reinheit:  99.88%
Target:  

Keap1-Nrf2

Forschungsgebiete:  

Cancer

Nrf2-IN-1 is an inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2). Nrf2-IN-1 is developed for the research of acute myeloid leukemia (AML) .
loading...
    loading...
9
9 Cited Publications
Art. -Nr.: HY-100548
CAS. Nr.: 1346607-05-3
Reinheit:  98.03%
Target:  

AMPK Autophagy Apoptosis

Forschungsgebiete:  

Cancer

GSK621 is a specific AMPK activator, with IC50 values of 13-30 μM for AML cells. GSK621 induces autophagy and apoptosis. GSK621 induces eiF2α phosphorylation-a hallmark of UPR activation .
loading...
    loading...
9
9 Cited Publications
Art. -Nr.: HY-12344A
CAS. Nr.: 2070015-17-5
Reinheit:  99.96%
Target:  

FLT3

Forschungsgebiete:  

Cancer

UNC2025 hydrochloride is a potent, ATP-competitive, highly orally active and BBB-permeable Mer/Flt3 inhibitor with IC50 values of 0.74 nM and 0.8 nM, respectively. UNC2025 hydrochloride is >45-fold selectivity for MERTK relative to Axl (IC50= 122 nM; Ki = 13.3 nM). UNC2025 hydrochloride exhibits an excellent PK properties, and can be used for the investigation of acute leukemia .
loading...
    loading...
8
8 Cited Publications
Art. -Nr.: HY-112852
CAS. Nr.: 1315330-17-6
Reinheit:  98.47%
Target:  

Src Apoptosis

Forschungsgebiete:  

Cancer

TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth .
loading...
    loading...
8
8 Cited Publications
Art. -Nr.: HY-124500
CAS. Nr.: 1834571-82-2
Reinheit:  99.93%
Target:  

STAT Apoptosis

Forschungsgebiete:  

Cancer

AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML) .
loading...
    loading...
7
7 Cited Publications
Art. -Nr.: HY-124629
CAS. Nr.: 2170606-74-1
Reinheit:  99.48%
Target:  

Apoptosis

Forschungsgebiete:  

Cancer

DB2313 is a potent inhibitor of transcription factor PU.1. DB2313 inhibits PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis in acute myeloid leukemia (AML) cells and has anticancer effects .
loading...
    loading...
7
7 Cited Publications
Art. -Nr.: HY-15187
CAS. Nr.: 885060-09-3
Reinheit:  99.59%
Synonyms: ARRY-520
Target:  

Kinesin Apoptosis

Forschungsgebiete:  

Cancer

Filanesib (ARRY-520) is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity .
loading...
    loading...
7
7 Cited Publications
Art. -Nr.: HY-15187C
CAS. Nr.: 1385020-40-5
Synonyms: ARRY-520 hydrochloride
Target:  

Kinesin Apoptosis

Forschungsgebiete:  

Neurological Disease Cancer

Filanesib (ARRY-520) hydrochloride is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity .
loading...
    loading...